Solasia Pharma K.K. (4597.T)
JPY 42.0
(2.44%)
JPY 42.0
(2.44%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -1.13 Billion JPY | 53.91% |
| 2022 | -2.47 Billion JPY | -2.15% |
| 2021 | -2.41 Billion JPY | 41.23% |
| 2020 | -4.11 Billion JPY | -133.6% |
| 2019 | -1.76 Billion JPY | 27.19% |
| 2018 | -2.42 Billion JPY | -139.68% |
| 2017 | -1 Billion JPY | -118.32% |
| 2016 | -462.47 Million JPY | 34.16% |
| 2015 | -702.42 Million JPY | -0.06% |
| 2014 | -702.01 Million JPY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -308 Million JPY | 12.5% |
| 2024 Q2 | -303 Million JPY | 1.62% |
| 2023 Q4 | -352 Million JPY | -8.64% |
| 2023 Q1 | -245 Million JPY | 52.79% |
| 2023 Q2 | -217 Million JPY | 11.43% |
| 2023 Q3 | -324 Million JPY | -49.31% |
| 2023 FY | -1.13 Billion JPY | 53.91% |
| 2022 Q3 | -723 Million JPY | -14.94% |
| 2022 Q1 | -600 Million JPY | -68.54% |
| 2022 FY | -2.47 Billion JPY | -2.15% |
| 2022 Q4 | -519 Million JPY | 28.22% |
| 2022 Q2 | -629 Million JPY | -4.83% |
| 2021 Q3 | -701 Million JPY | 2.64% |
| 2021 FY | -2.41 Billion JPY | 41.23% |
| 2021 Q1 | -642 Million JPY | 71.0% |
| 2021 Q2 | -720 Million JPY | -12.15% |
| 2021 Q4 | -356 Million JPY | 49.22% |
| 2020 Q2 | -734 Million JPY | -37.45% |
| 2020 Q3 | -633 Million JPY | 13.76% |
| 2020 FY | -4.11 Billion JPY | -133.6% |
| 2020 Q1 | -534 Million JPY | -201.69% |
| 2020 Q4 | -2.21 Billion JPY | -249.76% |
| 2019 Q3 | -575 Million JPY | -11.43% |
| 2019 Q1 | -494 Million JPY | 43.99% |
| 2019 FY | -1.76 Billion JPY | 27.19% |
| 2019 Q4 | -177 Million JPY | 69.22% |
| 2019 Q2 | -516 Million JPY | -4.45% |
| 2018 Q4 | -882 Million JPY | -43.41% |
| 2018 Q3 | -615 Million JPY | -2.84% |
| 2018 Q2 | -598 Million JPY | -84.0% |
| 2018 Q1 | -325 Million JPY | 44.47% |
| 2018 FY | -2.42 Billion JPY | -139.68% |
| 2017 Q1 | -243.33 Million JPY | -3628.07% |
| 2017 Q2 | -309.76 Million JPY | -27.3% |
| 2017 Q3 | 128.63 Million JPY | 141.53% |
| 2017 FY | -1 Billion JPY | -118.32% |
| 2017 Q4 | -585.22 Million JPY | -554.96% |
| 2016 Q4 | -6.52 Million JPY | 96.76% |
| 2016 FY | -462.47 Million JPY | 34.16% |
| 2016 Q3 | -201.59 Million JPY | -1.14% |
| 2016 Q2 | -199.33 Million JPY | -262.31% |
| 2016 Q1 | -55.01 Million JPY | 77.8% |
| 2015 Q3 | -211.57 Million JPY | 0.0% |
| 2015 Q4 | -247.82 Million JPY | -17.13% |
| 2015 FY | -702.42 Million JPY | -0.06% |
| 2014 FY | -702.01 Million JPY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 5.11 Billion JPY | 122.277% |
| Takeda Pharmaceutical Company Limited | 214.07 Billion JPY | 100.532% |
| Sumitomo Pharma Co., Ltd. | -354.19 Billion JPY | 99.678% |
| Shionogi & Co., Ltd. | 171.46 Billion JPY | 100.664% |
| Wakamoto Pharmaceutical Co.,Ltd. | -195.51 Million JPY | -482.576% |
| Nippon Shinyaku Co., Ltd. | 31.38 Billion JPY | 103.629% |
| Kaken Pharmaceutical Co., Ltd. | 9.51 Billion JPY | 111.973% |
| Eisai Co., Ltd. | 53.4 Billion JPY | 102.133% |
| Morishita Jintan Co., Ltd. | 716 Million JPY | 259.078% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.16 Billion JPY | 108.65% |
| Mochida Pharmaceutical Co., Ltd. | 5.8 Billion JPY | 119.628% |
| Fuso Pharmaceutical Industries,Ltd. | 1.96 Billion JPY | 157.994% |
| Nippon Chemiphar Co., Ltd. | -494 Million JPY | -130.567% |
| Tsumura & Co. | 20.01 Billion JPY | 105.69% |
| Kissei Pharmaceutical Co., Ltd. | 4.01 Billion JPY | 128.354% |
| Torii Pharmaceutical Co., Ltd. | 5.03 Billion JPY | 122.617% |
| Towa Pharmaceutical Co., Ltd. | 17.64 Billion JPY | 106.454% |
| Fuji Pharma Co., Ltd. | 3.85 Billion JPY | 129.523% |
| Zeria Pharmaceutical Co., Ltd. | 9.71 Billion JPY | 111.722% |
| KYORIN Holdings, Inc. | 6.01 Billion JPY | 118.942% |
| Taiko Pharmaceutical Co.,Ltd. | -3.07 Billion JPY | 63.007% |
| Daito Pharmaceutical Co.,Ltd. | 3.89 Billion JPY | 129.25% |
| SymBio Pharmaceuticals Limited | -811.66 Million JPY | -40.328% |
| MedRx Co., Ltd | -933 Million JPY | -22.079% |
| Mizuho Medy Co.,Ltd. | 5.15 Billion JPY | 122.108% |
| Modalis Therapeutics Corporation | -2.37 Billion JPY | 51.941% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 6.5 Billion JPY | 117.523% |
| Sawai Group Holdings Co., Ltd. | 18.88 Billion JPY | 106.031% |
| Cyfuse Biomedical K.K. | -697.43 Million JPY | -63.312% |
| Toho Holdings Co., Ltd. | 19.33 Billion JPY | 105.892% |
| Koa Shoji Holdings Co.,Ltd. | 4.38 Billion JPY | 125.991% |